RayzeBio inc (DELISTED) (RYZB:DL)
62.49
0.00 (0.00%)
USD |
NASDAQ |
Mar 06, 16:00
RayzeBio Cash from Operations (Quarterly): -45.26M for Sept. 30, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | -45.26M |
| Date | Value |
|---|---|
| September 30, 2022 | -40.89M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-45.26M
Minimum
Sep 2023
-40.89M
Maximum
Sep 2022
-43.08M
Average
-43.08M
Median
Cash from Operations (Quarterly) Benchmarks
| Bristol-Myers Squibb Co | 2.834B |
| Karuna Therapeutics Inc (DELISTED) | -111.06M |
| Ambrx Biopharma Inc (DELISTED) | -18.88M |
| Pfizer Inc | 1.09B |
| Mirati Therapeutics Inc (DELISTED) | -143.71M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -146.77M |
| Cash from Financing (Quarterly) | 314.84M |
| Free Cash Flow Per Share (Quarterly) | -5.005 |